Sarepta's (SRPT) DMD drug may be reviewed by FDA panel in January - Bloomberg

October 14, 2015 11:41 AM EDT Send to a Friend

Sarepta Therapeutics (NASDAQ: SRPT) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Sarepta's (SRPT) DMD drug may be reviewed by FDA panel in January - Bloomberg

Member Login

Free News Feed